^
    Back
    Association details:
    Biomarker:EGFR G719A + EGFR G779C
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

    Excerpt:
    Clinical outcomes for rare mutations or rare combinations of mutations.
    DOI:
    10.1158/1078-0432.CCR-09-0888